This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 Sep 11;371(11):1067-9.

doi: 10.1056/NEJMe1409306. Epub 2014 Sep 3.

Targeting the androgen receptor in prostate cancer--a resilient foe

Peter S Nelson¹

Affiliations

PMID: 25184629
DOI: 10.1056/NEJMe1409306

Editorial

Targeting the androgen receptor in prostate cancer--a resilient foe

Peter S Nelson. N Engl J Med. 2014.

. 2014 Sep 11;371(11):1067-9.

doi: 10.1056/NEJMe1409306. Epub 2014 Sep 3.

Author

Peter S Nelson¹

Affiliation

¹ From the Fred Hutchinson Cancer Research Center, Seattle.

PMID: 25184629
DOI: 10.1056/NEJMe1409306

No abstract available

PubMed Disclaimer

Comment on

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.

Similar articles

Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J, Schrader AJ, Luedeke M. Steinestel J, et al. N Engl J Med. 2014 Dec 4;371(23):2234. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470703 No abstract available.
Resistance to androgen-pathway drugs in prostate cancer.
Ozaki Y, Miura Y, Takano T. Ozaki Y, et al. N Engl J Med. 2014 Dec 4;371(23):2233-4. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470702 No abstract available.
Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA, Akıncı MB, Yalçın B. Şendur MA, et al. N Engl J Med. 2014 Dec 4;371(23):2233. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470701 No abstract available.
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G, Antonarakis ES. Attard G, et al. Nat Rev Urol. 2016 Dec;13(12):697-698. doi: 10.1038/nrurol.2016.212. Epub 2016 Nov 2. Nat Rev Urol. 2016. PMID: 27804988 Review. No abstract available.
New therapeutic agents for castration-refractory prostate cancer.
Patten DY, Sartor O. Patten DY, et al. Clin Genitourin Cancer. 2009 Aug;7(2):E4-6. doi: 10.3816/CGC.2009.n.013. Clin Genitourin Cancer. 2009. PMID: 19692323 Review. No abstract available.

See all similar articles

Cited by

Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins.
Dyshlovoy SA, Mansour WY, Ramm NA, Hauschild J, Zhidkov ME, Kriegs M, Zielinski A, Hoffer K, Busenbender T, Glumakova KA, Spirin PV, Prassolov VS, Tilki D, Graefen M, Bokemeyer C, von Amsberg G. Dyshlovoy SA, et al. Sci Rep. 2024 May 23;14(1):11788. doi: 10.1038/s41598-024-62358-8. Sci Rep. 2024. PMID: 38783016 Free PMC article.
Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries.
Montuori E, Hyde CAC, Crea F, Golding J, Lauritano C. Montuori E, et al. Int J Mol Sci. 2023 Jan 11;24(2):1435. doi: 10.3390/ijms24021435. Int J Mol Sci. 2023. PMID: 36674949 Free PMC article. Review.
New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide.
Dyshlovoy SA, Zhuravleva OI, Hauschild J, Busenbender T, Pelageev DN, Yurchenko AN, Khudyakova YV, Antonov AS, Graefen M, Bokemeyer C, von Amsberg G. Dyshlovoy SA, et al. Mar Drugs. 2023 Jan 14;21(1):54. doi: 10.3390/md21010054. Mar Drugs. 2023. PMID: 36662227 Free PMC article.
New Guanidine Alkaloids Batzelladines O and P from the Marine Sponge Monanchora pulchra Induce Apoptosis and Autophagy in Prostate Cancer Cells.
Dyshlovoy SA, Shubina LK, Makarieva TN, Guzii AG, Hauschild J, Strewinsky N, Berdyshev DV, Kudryashova EK, Menshov AS, Popov RS, Dmitrenok PS, Graefen M, Bokemeyer C, von Amsberg G. Dyshlovoy SA, et al. Mar Drugs. 2022 Nov 25;20(12):738. doi: 10.3390/md20120738. Mar Drugs. 2022. PMID: 36547885 Free PMC article.
Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer Cells.
Dyshlovoy SA, Busenbender T, Hauschild J, Girich EV, Kriegs M, Hoffer K, Graefen M, Yurchenko AN, Bokemeyer C, von Amsberg G. Dyshlovoy SA, et al. Mar Drugs. 2022 Sep 23;20(10):597. doi: 10.3390/md20100597. Mar Drugs. 2022. PMID: 36286421 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information